Cargando…

New frontiers in the medical management of gastrointestinal stromal tumours

The tyrosine kinase inhibitor (TKI) imatinib has radically changed the natural history of KIT-driven gastrointestinal stromal tumours (GISTs). Approved second-line and third-line medical therapies are represented by the TKIs sunitinib and regorafenib, respectively. While imatinib remains the cardina...

Descripción completa

Detalles Bibliográficos
Autores principales: Mazzocca, Alessandro, Napolitano, Andrea, Silletta, Marianna, Spalato Ceruso, Mariella, Santini, Daniele, Tonini, Giuseppe, Vincenzi, Bruno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535752/
https://www.ncbi.nlm.nih.gov/pubmed/31205499
http://dx.doi.org/10.1177/1758835919841946
_version_ 1783421622887120896
author Mazzocca, Alessandro
Napolitano, Andrea
Silletta, Marianna
Spalato Ceruso, Mariella
Santini, Daniele
Tonini, Giuseppe
Vincenzi, Bruno
author_facet Mazzocca, Alessandro
Napolitano, Andrea
Silletta, Marianna
Spalato Ceruso, Mariella
Santini, Daniele
Tonini, Giuseppe
Vincenzi, Bruno
author_sort Mazzocca, Alessandro
collection PubMed
description The tyrosine kinase inhibitor (TKI) imatinib has radically changed the natural history of KIT-driven gastrointestinal stromal tumours (GISTs). Approved second-line and third-line medical therapies are represented by the TKIs sunitinib and regorafenib, respectively. While imatinib remains the cardinal drug for patients with GISTs, novel therapies are being developed and clinically tested to overcome the mechanisms of resistance after treatments with the approved TKI, or to treat subsets of GISTs driven by rarer molecular events. Here, we review the therapy of GISTs, with a particular focus on the newest drugs in advanced phases of clinical testing that might soon change the current therapeutic algorithm.
format Online
Article
Text
id pubmed-6535752
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-65357522019-06-14 New frontiers in the medical management of gastrointestinal stromal tumours Mazzocca, Alessandro Napolitano, Andrea Silletta, Marianna Spalato Ceruso, Mariella Santini, Daniele Tonini, Giuseppe Vincenzi, Bruno Ther Adv Med Oncol Review The tyrosine kinase inhibitor (TKI) imatinib has radically changed the natural history of KIT-driven gastrointestinal stromal tumours (GISTs). Approved second-line and third-line medical therapies are represented by the TKIs sunitinib and regorafenib, respectively. While imatinib remains the cardinal drug for patients with GISTs, novel therapies are being developed and clinically tested to overcome the mechanisms of resistance after treatments with the approved TKI, or to treat subsets of GISTs driven by rarer molecular events. Here, we review the therapy of GISTs, with a particular focus on the newest drugs in advanced phases of clinical testing that might soon change the current therapeutic algorithm. SAGE Publications 2019-05-17 /pmc/articles/PMC6535752/ /pubmed/31205499 http://dx.doi.org/10.1177/1758835919841946 Text en © The Author(s), 2019 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Review
Mazzocca, Alessandro
Napolitano, Andrea
Silletta, Marianna
Spalato Ceruso, Mariella
Santini, Daniele
Tonini, Giuseppe
Vincenzi, Bruno
New frontiers in the medical management of gastrointestinal stromal tumours
title New frontiers in the medical management of gastrointestinal stromal tumours
title_full New frontiers in the medical management of gastrointestinal stromal tumours
title_fullStr New frontiers in the medical management of gastrointestinal stromal tumours
title_full_unstemmed New frontiers in the medical management of gastrointestinal stromal tumours
title_short New frontiers in the medical management of gastrointestinal stromal tumours
title_sort new frontiers in the medical management of gastrointestinal stromal tumours
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535752/
https://www.ncbi.nlm.nih.gov/pubmed/31205499
http://dx.doi.org/10.1177/1758835919841946
work_keys_str_mv AT mazzoccaalessandro newfrontiersinthemedicalmanagementofgastrointestinalstromaltumours
AT napolitanoandrea newfrontiersinthemedicalmanagementofgastrointestinalstromaltumours
AT sillettamarianna newfrontiersinthemedicalmanagementofgastrointestinalstromaltumours
AT spalatocerusomariella newfrontiersinthemedicalmanagementofgastrointestinalstromaltumours
AT santinidaniele newfrontiersinthemedicalmanagementofgastrointestinalstromaltumours
AT toninigiuseppe newfrontiersinthemedicalmanagementofgastrointestinalstromaltumours
AT vincenzibruno newfrontiersinthemedicalmanagementofgastrointestinalstromaltumours